Le Lézard
Classified in: Health
Subjects: WOM, POL, RCL, CFG

Advisory - Demulen 30 birth control pills: Packages containing broken or chipped pills


OTTAWA, June 1, 2018 /CNW/ -

Issue
Pfizer Canada Inc. has notified Health Canada that it has received complaints of broken or chipped pills involving Demulen 30, a prescription birth control pill. Health Canada has previously communicated on similar issues involving two other brands of birth control pills. Health Canada continues to remind women to check their packages of birth control pills and to report problems if they see them. If you notice anything unusual in the package, such as missing or damaged pills, you should return the package to the pharmacy for replacement as soon as possible. Skipping a dose because the pill is missing, or taking a damaged (for example, chipped or fragmented) pill, may increase the risk of pregnancy because less active ingredient may be taken. It is important to get a replacement package as soon as possible to avoid missing any doses.

Who is affected

Affected products
Demulen 30 birth control packages that contain damaged or unusual pills.

What consumers should do

Additional information for health professionals:

What Health Canada is doing
Health Canada continues to follow up with Pfizer Canada to make sure appropriate measures are taken to correct any quality issues. We will continue to monitor and assess the need for further action, and will update consumers and health care professionals as appropriate.

Background
Health Canada has recently communicated about instances of quality concerns involving Alesse and Alysena birth control pills (see links below).

Pfizer Canada has advised that it has received complaints of broken or chipped pills in packages of Demulen 30 (28 day package, DIN 00471526). While the company indicates that the rate of occurrence is very low, Health Canada is reminding women to always check their pills before taking them. Health Canada is providing this advice as a general reminder and is not suggesting that there are issues with all birth control pills.

Related links

For more information
Stay connected with Health Canada and receive the latest advisories and product recalls using social media tools.

Également disponible en français

 

SOURCE Health Canada


These press releases may also interest you

26 avr 2024
The report titled "Anti-Mullerian Hormone Test Market by Product (POC Testing, Self-check Kits), End-User (Commercial Labs, Research & development), Distribution, Use - Global Forecast 2024-2030" is now available on 360iResearch.com's offering,...

26 avr 2024
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...

26 avr 2024
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...

26 avr 2024
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...

26 avr 2024
David J. Dykeman, co-chair of the Life Sciences & Medical...

26 avr 2024
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community.  Aspire Health experienced a data security incident that may have involved personal and...



News published on and distributed by: